Merck & Co., Inc. (ETR:6MK)

Germany flag Germany · Delayed Price · Currency is EUR
70.00
+0.80 (1.16%)
Jul 8, 2025, 5:35 PM CET
-39.97%
Market Cap 173.14B
Revenue (ttm) 59.14B
Net Income (ttm) 16.13B
Shares Out n/a
EPS (ttm) 6.36
PE Ratio 10.73
Forward PE 9.00
Dividend 2.91 (4.23%)
Ex-Dividend Date Jun 16, 2025
Volume 1,651
Average Volume 3,208
Open 68.90
Previous Close 69.20
Day's Range 68.80 - 70.30
52-Week Range 65.50 - 120.00
Beta 0.40
RSI 53.60
Earnings Date Jul 29, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange Deutsche Börse Xetra
Ticker Symbol 6MK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus

I present my top 10 high-yield dividend stocks for July 2025, screened for strong yields, large market caps, and attractive valuations. The list includes Chevron, Pfizer, PepsiCo, Ares Capital, BB Seg...

1 day ago - Seeking Alpha

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...

3 days ago - Seeking Alpha

Dr. Rasha Kelej Meets Mauritius President to Strengthen Partnership to Improve Access to Innovative and Equitable Healthcare and Empower Women in STEM

Senator, Dr. Rasha Kelej, CEO of Merck Foundation, the philanthropic arm of Merck KGaA Germany met HIS EXCELLENCY MR. DHARAMBEER GOKHOOL, The President of Republic of Mauritius, during a high-level me...

4 days ago - Business Upturn

Tech stocks soar: Semiconductors and software lead market gains

Sector Overview: Tech Takes the Lead The US stock market exhibited a remarkable tilt towards the technology sector today, with tech giants and semiconductors driving considerable gains. The sector at ...

5 days ago - Forexlive

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

5 days ago - Benzinga

Merck's Hypertension Drug On FDA Fast Track For Label Expansion

The U.S. Food and Drug Administration (FDA) has accepted and granted priority review for Merck & Co. Inc.’s (NYSE: MRK) new supplemental Biologics License Application (sBLA) seeking approval to updat...

6 days ago - Benzinga

FDA Grants Priority Review for WINREVAIR (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplementa...

6 days ago - Wallstreet:Online

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori...

6 days ago - Business Wire

Top 15 High-Growth Dividend Stocks For July 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...

7 days ago - Seeking Alpha

Flow of funds moves into Dow and small cap stocks.

The market rotated out of the large-cap tech stocks today. Markets got a little spooked by better than expected JOLT job openings and the realization that July is probably not a month for a rate cut. ...

7 days ago - Forexlive

Top 10 High-Yield Dividend Stocks For July 2025

My July 2025 watchlist focuses on high-yield, attractively valued stocks, aiming for a 12% long-term CAGR and outperforming benchmarks. Since its inception, my watchlist has a CAGR of 15.11%, performi...

7 days ago - Seeking Alpha

Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit in Dubai

DUBAI, United Arab Emirates--(BUSINESS WIRE)-- #CEO--Merck Foundation conducted the 7th Edition of Merck Foundation First Ladies Initiative - MFFLI Summit 2025 in Dubai, United Arab Emirates.

7 days ago - Business Wire

Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET ...

7 days ago - Wallstreet:Online

Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29.

7 days ago - Business Wire

Peering Into Merck & Co's Recent Short Interest

Merck & Co's (NYSE: MRK) short percent of float has risen 3.92% since its last report. The company recently reported that it has 35.80 million shares sold short , which is 1.59% of all regular shares...

8 days ago - Benzinga

Merck: Don't Let Today's Bargain Opportunity Pass You By

Merck remains a top Big Pharma brand with strong management, expected sales growth, and high profit margins, helped by the revolutionary Keytruda invention.

9 days ago - Seeking Alpha

Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)

Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant s...

11 days ago - Seeking Alpha

40% Upside For Merck Stock?

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipelin...

11 days ago - Forbes

US stocks threatens to close at record levels but closes just off record levels

The broader stock indices threatened to close at record levels with the S&P index getting within one point of a record high level. The comes in at 6147.43. The high price today reached 6146.52. The NA...

12 days ago - Forexlive

Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has previously made statements skeptical of vaccines, is now recommending the respiratory syncytial virus (RSV) vaccine for infants...

12 days ago - Fast Company

Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise

After years of struggling with market share losses and uneven execution, Elanco Animal Health Incorporated (NYSE: ELAN) appears to be turning a corner . What Happened : Investor meetings hosted by Wi...

12 days ago - Benzinga